Key result
ECMOLife system achieves 100% procedural survival with minimal hemolysis in critically ill neonates.
Why the study?
Magnetic levitation technology in centrifugal pumps may reduce hemolysis in pediatric ECMO, but experience with the new ECMOLife pump in newborns was lacking.
Does the ECMOLife System provide safe and effective mechanical support in newborn patients with refractory cardiac and/or respiratory failure?
Case Report (n=4)
Does the ECMOLife System provide safe and effective mechanical support in newborn patients with refractory cardiac and/or respiratory failure?
Answers are grounded in this paper and cite their sources.
The ECMOLife magnetic levitation centrifugal pump appears safe and effective for newborn ECMO support, with low hemolysis.
Background and Objectives: Pediatric ECMO is a valid support mechanism for refractory cardiac and/or respiratory failure. Magnetic levitation technology applied to the centrifugal pump has reduced the hemolysis caused by this procedure, which can be particularly dangerous, especially in neonates and small children. ECMOLife, a new magnetic levitation centrifugal pump, has been introduced for these patients. Materials and Methods: Four patients were supported with the ECMOLife System in a newborn setting, with veno-venous application in two cases and veno-arterial in the other two. All parameters related to pump functioning, anticoagulation, hemolysis, and inflammation were recorded for the duration of the support. Results: All patients survived the procedure, in three cases achieving recovery, while one veno-arterial ECMO was switched to VAD, and then the patient underwent heart transplantation. All recorded parameters were compatible with clinical conditions. In particular, free haemoglobin was close to 0 g/L in all recorded samples. The possibility of monitoring pump functioning parameters, venous and arterial O2 saturation, and venous and arterial pressures creates an opportunity to check the adequacy of mechanical support for the clinical condition of the patient. Conclusions: This is the first reported experiment in a newborn setting with ECMOLife mechanical support. At present, ECMOLife represents the only system with a newborn and pediatric pump, allowing for the continuous monitoring of perfusion and hemodynamic parameters, with a large number of facilities for transportation available.
No takes yet. Share an insight, caveat, or question.
Napoleone et al. (2025) conducted a case report in Refractory cardiac and/or respiratory failure (n=4). ECMOLife System was evaluated on Survival and pump functioning parameters (including hemolysis).
Synapse has enriched 10 related papers. Consider them for comparative context: